title: Determination and comparison of the pressor effect of tyramine during long-term moclobemide and tranylcypromine treatment in healthy volunteers.
abstract: Monoamine oxidase inhibitors can elicit increases in systolic blood pressure after tyramine ingestion (cheese effect). Moclobemide is a new, reversible, preferential monoamine oxidase A inhibitor with antidepressant properties. Its potentiation of the tyramine pressor effect during 200 mg t.i.d. chronic treatment was compared with tranylcypromine, 10 mg b.i.d., in a double-blind, parallel-group, placebo-controlled study (n = 16). Tyramine was mixed with food and ingested in increasing daily doses, during a normal meal, until a systolic blood pressure increase of at least 30 mm Hg was achieved (tyramine 30). When compared with the usual fasting oral tyramine tests performed in the same subjects, the mean tyramine 30 dose with a meal was 2.8 times higher. The mean tyramine 30 dose with a meal decreased from 1450 mg (range, 800 to 2000 mg) during placebo to 306 mg (range, 150 to 500 mg) during moclobemide (factor, 5.0) and from 1200 mg (range, 1000 to 1600 mg) during placebo to 35 mg (range, 20 to 50 mg) during tranylcypromine (factor, 38.2). The duration of the systolic blood pressure increase was longer with tranylcypromine (126 minutes) than with moclobemide (69 minutes) (p less than 0.01).
authors.affiliation: Department of Clinical Pharmacology, Hôpital Pitié-Salpétrière, Paris, France.
authors.forename: I
authors.initials: I
authors.lastname: Berlin
authors.forename: R
authors.initials: R
authors.lastname: Zimmer
authors.forename: A
authors.initials: A
authors.lastname: Cournot
authors.forename: C
authors.initials: C
authors.lastname: Payan
authors.forename: A M
authors.initials: AM
authors.lastname: Pedarriosse
authors.forename: A J
authors.initials: AJ
authors.lastname: Puech
mesh_terms: D000284:Administration, Oral; D000328:Adult; D001549:Benzamides / Q000009:adverse effects / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects*; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004357:Drug Synergism; D006801:Humans; D008297:Male; D020912:Moclobemide; D008996:Monoamine Oxidase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D010919:Placebos; D011311:Pressoreceptors / Q000187:drug effects; D011897:Random Allocation; D012016:Reference Values; D014191:Tranylcypromine / Q000009:adverse effects / Q000627:therapeutic use*; D014439:Tyramine / Q000008:administration & dosage / Q000494:pharmacology*
chemical_list: D001549:Benzamides; D008996:Monoamine Oxidase Inhibitors; D010919:Placebos; D014191:Tranylcypromine; D020912:Moclobemide; D014439:Tyramine